Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Digital Health Meets AI -CSE: ALEN.U (click to learn more) New Gold Opportunities in the Cariboo Region (CSE:GCC) (OTC:GCCFF) (click to learn more) Why Herbal Dispatch (CSE:HERB) Is Getting Attention (click to learn more) Atlas Salt Expands MOU with Sandvik Mining Supporting Great Atlantic Salt Project (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Stock Quote Today & Recent News Rhythm Pharmaceuticals Inc RYTM

Healthcare Biotechnology
Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company’s lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:RYTM)

Rhythm Pharmaceuticals Announces Participation in Upcoming Guggenheim Biotech Summit

GlobeNewswire 8 days ago

Rhythm Pharmaceuticals Announces Preliminary, Unaudited Fourth Quarter and Full Year 2025 Net Product Revenues and Upcoming Milestones

GlobeNewswire January 9, 2026

Rhythm Pharmaceuticals Announces Preliminary Data from Exploratory Phase 2 Trial that showed Setmelanotide Demonstrated Positive Efficacy Signal in Prader-Willi Syndrome

GlobeNewswire December 11, 2025

Rhythm Pharmaceuticals to Announce Preliminary Data from Exploratory Phase 2 Trial Evaluating Setmelanotide in Prader-Willi Syndrome

GlobeNewswire December 10, 2025

Rhythm Pharmaceuticals Announces Presentation of Four Datasets at ObesityWeek® 2025

GlobeNewswire November 10, 2025

Rhythm Pharmaceuticals Announces FDA Extension of Review Period for IMCIVREE® (setmelanotide) for Patients with Acquired Hypothalamic Obesity

GlobeNewswire November 7, 2025

Rhythm Pharmaceuticals Announces Public Reimbursement for IMCIVREE® (setmelanotide) in Canada in Five Provinces and Under the Federal Non-Insured Health Benefits Program

GlobeNewswire November 5, 2025

Rhythm Pharmaceuticals Reports Third Quarter 2025 Financial Results and Business Update

GlobeNewswire November 4, 2025

Rhythm Pharmaceuticals to Report Third Quarter 2025 Financial Results on Tuesday, November 4, 2025

GlobeNewswire October 21, 2025
View More News ››

Opinion & Analysis (NDAQ:RYTM)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:RYTM)

Be the first to post on this bullboard.

DRC Gold Corp.

DRC Gold Corp.

DRC Gold Corp. is an exploration and development company formed for the purposes of acquiring, exploring and if warranted and ...
View More »

Podcasts